racemetirosine has been researched along with Parkinson Disease, Secondary in 5 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 7.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| "The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats." | 3.70 | Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Wolfarth, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sotnikova, TD | 1 |
| Beaulieu, JM | 1 |
| Barak, LS | 1 |
| Wetsel, WC | 1 |
| Caron, MG | 1 |
| Gainetdinov, RR | 1 |
| Fahn, S | 1 |
| Laruelle, M | 1 |
| D'Souza, CD | 1 |
| Baldwin, RM | 1 |
| Abi-Dargham, A | 1 |
| Kanes, SJ | 1 |
| Fingado, CL | 1 |
| Seibyl, JP | 1 |
| Zoghbi, SS | 1 |
| Bowers, MB | 1 |
| Jatlow, P | 1 |
| Charney, DS | 1 |
| Innis, RB | 1 |
| Hughes, NR | 1 |
| McKnight, AT | 1 |
| Woodruff, GN | 1 |
| Hill, MP | 1 |
| Crossman, AR | 1 |
| Brotchie, JM | 1 |
| Lorenc-Koci, E | 1 |
| Wolfarth, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Carbidopa/l-Dopa and Carbidopa/l Dopa/Entacapone on Synaptic Dopamine in Parkinson's Patients: An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)[NCT00200447] | Phase 2 | 3 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for racemetirosine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Topics: alpha-Methyltyrosine; Amphetamines; Animals; Antiparkinson Agents; Basal Ganglia; Blepharoptosis; Di | 2005 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
Imaging D2 receptor occupancy by endogenous dopamine in humans.
Topics: Adult; Affect; alpha-Methyltyrosine; Animals; Benzamides; Brain; Dopamine; Enzyme Inhibitors; Homova | 1997 |
Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism.
Topics: alpha-Methyltyrosine; Animals; Antiparkinson Agents; Benzeneacetamides; Benzofurans; Dose-Response R | 1998 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; | 1999 |